ArticleCell communication and signaling : CCS2026
CD80
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundTc17 cells (IL-17 + CD8+T) are found in many inflammatory diseases. However, the distribution, regulation, and function of Tc17 cells in ApoE deficient-induced atherosclerosis are currently largely unexplored.
methodsThe percentage of Tc17 cells, monocytes and IL-1β+ monocytes in blood of hyperlipidemic patients or healthy donors were analyzed by flow cytometry. The content of IL-1β in plasma was detected by ELISA. Correlations between parameters of clinical samples were assessed using Spearman r correlation analysis or linear regression analysis as appropriate. Aorta, blood, spleen, and bone marrow of atherosclerotic mice with different stages were collected for flow cytometry to analyze the percentage of Tc17 cells and monocytes/macrophages. Hearts were collected for Oil Red O staining, Masson’s staining, immunofluorescence staining or immunohistochemistry staining. GEO database (GSE43292) was used to analyze the expression of Tc17 cell-related inducers in plaques of AS patients. CD8+T cells and macrophages were isolated for ex vivo function assays. Adoptive transfer and IL-1β neutralization experiments were utilized for in vivo mechanism assays.
resultsHigher populations of Tc17 cells, IL-1β+monocytes or CD80+ monocytes were found in the peripheral blood of hyperlipidemic patients compared to that in healthy donors. In addition, positive correlation between Tc17 cells and CD80+ monocytes was observed in hyperlipidemic patients. Furthermore, Tc17 cells and CD80+ monocytes/macrophages increased in the aorta, blood, spleen, and bone marrow of atherosclerotic mice, reaching the highest level on week 12 post feeding. Based on the analysis of GSE43292, we found increased IL-1β expression in AS plaques, not the other inducing differentiation factors of Tc17 cells, compared to normal tissues. Finally, ex vivo co-culture and transwell experiment and in vivo adoptive transfer and IL-1β neutralization experiments confirmed that CD80+ macrophages promoted Tc17 cells expansion by IL-1β in vascular lesions and facilitated murine atherosclerotic progression.
conclusionThe present results show that suppressing IL-1β expression by preventing CD80+ macrophage polarization may alleviate atherosclerosis through the reduction of Tc17 cells in atherosclerotic lesions. Our study demonstrates that decreasing Tc17 cells population by the inhibition of CD80+ macrophage-derived IL-1β is a potentially promising therapeutic strategy for the treatment of atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.